

**AMENDMENT IN THE NATURE OF A SUBSTITUTE
TO H.R. 5353
OFFERED BY MR. LANCE OF NEW JERSEY**

Strike all after the enacting clause and insert the following:

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Eliminating Opioid Re-
3 lated Infectious Diseases Act of 2018”.

4 **SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM**
5 **OF SURVEILLANCE AND EDUCATION RE-**
6 **GARDING INFECTIONS ASSOCIATED WITH IL-**
7 **LICIT DRUG USE AND OTHER RISK FACTORS.**

8 Section 317N of the Public Health Service Act (42
9 U.S.C. 247b–15) is amended to read as follows:

10 **“SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING**
11 **INFECTIONS ASSOCIATED WITH ILLICIT**
12 **DRUG USE AND OTHER RISK FACTORS.**

13 “(a) IN GENERAL.—The Secretary may (directly and
14 through grants to public and nonprofit private entities)
15 provide for programs for the following:

16 “(1) To cooperate with the States in imple-
17 menting or maintaining a surveillance system to de-
18 termine the incidence of infections commonly associ-

1 ated with illicit drug use, including infections com-
2 monly associated with injection drug use such as
3 viral hepatitis, human immunodeficiency virus, and
4 infective endocarditis, and to assist the States in de-
5 termining the prevalence of such infections, which
6 may include the reporting of cases of such infec-
7 tions.

8 “(2) To identify, counsel, and offer testing to
9 individuals who are at risk of infections as a result
10 of injection drug use, receiving blood transfusions
11 prior to July 1992, or other risk factors.

12 “(3) To provide appropriate referrals for coun-
13 seling, testing, and medical treatment of individuals
14 identified under paragraph (2) and to ensure, to the
15 extent practicable, the provision of appropriate fol-
16 low-up services.

17 “(4) To develop and disseminate public infor-
18 mation and education programs for the detection
19 and control of infections described in paragraph (1),
20 with priority given to high-risk populations as deter-
21 mined by the Secretary.

22 “(5) To improve the education, training, and
23 skills of health professionals in the detection and
24 control of infections and the coordination of treat-
25 ment of addiction and infectious diseases described

1 in paragraph (1), with priority given to substance
2 use disorder treatment providers, pediatricians and
3 other primary care providers, obstetrician-gyne-
4 cologists, infectious diseases clinicians, and HIV cli-
5 nicians.

6 “(b) LABORATORY PROCEDURES.—The Secretary
7 may (directly or through grants to public and nonprofit
8 private entities) carry out programs to provide for im-
9 provements in the quality of clinical-laboratory procedures
10 regarding infections described in subsection (a)(1).

11 “(c) DEFINITIONS.—In this section, the term ‘injec-
12 tion drug use’ means—

13 “(1) intravenous administration of a substance
14 in schedule I under section 202 of the Controlled
15 Substances Act;

16 “(2) intravenous administration of a substance
17 in schedule II, III, IV, or V under section 202 of the
18 Controlled Substances Act that has not been ap-
19 proved for intravenous use under—

20 “(A) section 505 of the Federal Food,
21 Drug and Cosmetic Act; or

22 “(B) section 351 of the Public Health
23 Service Act; or

24 “(3) intravenous administration of a substance
25 in schedule II, III, IV, or V under section 202 of the

1 Controlled Substances Act that has not been pre-
2 scribed to the person using the substance.

3 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the
4 purpose of carrying out this section, there are authorized
5 to be appropriated \$40,000,000 for each of the fiscal years
6 2019 through 2023.”.

